

Poster ID: LB1786

Transient epigenetic reprogramming by mRNA for skin rejuvenation

Christine Monteleon, Ph.D.¹, Siddarth Menon, Ph.D.¹, Jordan Spice¹, Aabida Mohammed¹, Vittorio Sebastiano, Ph.D.¹, and Edward Hsia, Ph.D.¹


1 Turn Biotechnologies, Inc. 2 Institute for Stem Cell Biology and Regenerative Medicine and the Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA


Introduction

In recent years, epigenetic reprogramming has come to the forefront of tissue regeneration and is based on the concept that as cells age, their nuclear regulation of gene expression becomes aberrant, leading to senescence and disruption of cellular homeostasis¹. In aged skin, this manifests in many ways, such as loss of extracellular matrix (ECM) deposition and increased oxidative stress, which are the molecular hallmarks underlying poor skin quality²⁻⁴.

Epigenetic Reprogramming of Aging (ERATM) is a proprietary cocktail of mRNA encoding transcription factors that when delivered transiently, restores cellular gene expression back to a more youthful state without changing the cell's identity. ERATM has the potential to disrupt the practice of aesthetic medicine by complementing and/or possibly replacing many of the skin rejuvenation treatments used today. By reprogramming cells at the epigenetic level to a more youthful state without changing their identity, ERATM has the potential to address multiple aspects of aged skin in a more natural, non-invasive manner, with long-lasting effects.


ERA™: solid lipid nanoparticle containing mRNA that encodes reprogramming factors






Partial Reprogramming with ERA™

Methods



















Analysis
• Immunofluorescence

FIGURE 1



mean of normalized counts










FIGURE 2

Untreated










ERA-treated

Transient reprogramming with ERATM Has a Strong Global Transcriptional Effect on Adult Dermal Fibroblasts That Amounts to an Overall Enrichment of ECM Protein Deposition and Downregulation of Cytokine Signaling. Primary adult human dermal fibroblasts were transfected with ERA and harvested on Day 6 for bulk RNAseq analysis. A) MA plot showing the wide distribution of differentially expressed genes (in red). B) Volcano plot showing distribution of significantly differentially downregulated (blue) and upregulated (red) genes. C) Gene ontology (GO) analysis of ERA-treated fibroblasts (relative to control) showing the top 10 upregulated and downregulated GO categories. D) Hierarchical clustering heatmap of the top 50 most significantly differentially expressed genes between ERA-treated and Control groups. E) Selected genes of interest related to skin quality that were significantly up- or down-regulated


SOD2 and MMP1 Protein Expression is Decreased in Dermal Fibroblasts Treated with ERATM. Primary adult human dermal fibroblasts were transfected with ERA and fixed on Day 6 for analysis by quantitative immunofluorescence. Both SOD2 (oxidative stress marker) and MMP1 are known to be increased in aged skin.

FIGURE 3




Treatment with ERATM Results in a Broad Panel of Changes Related to Aging and Skin Quality. Primary adult human dermal fibroblasts were transfected with ERA and fixed on Day 6 for analysis by quantitative immunofluorescence. SOD2, MMP1, MMP9, and p16 (senescence marker) are known to be increased in aged skin, while H3K9me3 (rejuvenation marker) is known to be decreased.

FIGURE 4



Cell Proliferation is Increased in Fibroblasts Treated with ERA™ Primary adult human dermal fibroblasts were transfected with ERA and fixed/counted on Day 6.

FIGURE 5



ERATM Rejuvenates Ex Vivo Human Skin. Freshly excised abdominal skin was obtained from a 52yo female undergoing elective surgery. 12mm punch biopsies were put into culture and intradermally injected with ERA. On Day 6, skin explant cultures were processed for immunofluorescence. Collagen VII is a key ECM protein that maintains the integrity of the dermal-epidermal junction and is known to decrease with age.

Conclusion


Compared to controls, human adult fibroblasts treated with ERA displayed:

- A global change in the transcriptome that amounted to an overall deposition of ECM
- proteins and decreased cytokine signaling
 Increased gene expression of various collagens and other ECM proteins
- Decreased gene and protein expression of MMPs and oxidative stress markers
- Decreased protein expression of the senescence marker p16
- Increased protein expression of the rejuvenation marker H3K9me3
 Increased cell proliferation


Compared to controls, human skin explants treated with ERA displayed:

- Decreased protein expression of the oxidative stress marker, SOD2
- Increased protein expression of collagen VII

Discussion



ERA™ increases fibroblast proliferation and ECM protein deposition while simultaneously reversing the intrinsic hallmarks of aging. These molecular changes suggest that ERA™ has the potential to reverse the clinical signs of aging skin.



SCAN TO LEARN MORE